Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II TrialMeletios Α. Dimopoulos, Pieter Sonneveld, Katja Weisel et al.|Journal of Clinical Oncology|2018Cited by 71
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow‐up of a multicenter, retrospective real‐world experience with 321 cases outside of controlled clinical trialsEnrica Antonia Martino, Pellegrino Musto, G. Tarantini et al.|Hematological Oncology|2024Cited by 7
Safety of Treatment (Tx) with Pomalidomide (POM) and Low-Dose Dexamethasone (LoDEX) in Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM) and Renal Impairment (RI), Including Those on DialysisKarthik Ramasamy, Pieter Sonneveld, Meletios Α. Dimopoulos et al.|Blood|2015Cited by 6
Defibrotide Low-Dose Continuous Infusion from Day +1 Until Day +21 after Allogeneic Stem Cell Transplantation as Prophylaxis of Veno-Occlusive Disease (VOD) of the Liver. A Single Centre Experience.Alessandro Bonini, Luigi Gugliotta, Paolo Avanzini et al.|Blood|2007Cited by 3
A Noninterventional, Observational, European Post-Authorization Safety Study of Patients With Relapsed/Refractory Multiple Myeloma Treated With LenalidomideBarbara Gamberi, Igor Wolfgang Blau, Christian Berthou et al.|Clinical Lymphoma Myeloma & Leukemia|2020Cited by 2